Top AMA Morning Rounds® News: Week of October 17, 2022

Read AMA Morning Rounds®’ most popular stories in medicine and public health for the week of October 17, 2022 to October 10, 2022 21st, 2022.

Bloomberg (10/20, Rutherford, Milton) reports that “COVID-19 vaccinations should be added to 2023 childhood and adult immunization schedules,” according to the CDC’s Advisory Committee on Immunization Practices. The panel “voted 15-0 Thursday to recommend COVID-19 imaging from Moderna Inc., Pfizer Inc. and Novavax Inc.”

The AP (10/20, Stobbe) reports that this “decision has no immediate impact” but instead “would place the recordings on the annually updated, formal lists of which vaccinations to take.” [physicians] should routinely offer their patients vaccinations against polio, measles and hepatitis.”

The Washington Post (10/19, McGinley) reports that the FDA on Wednesday “granted an emergency use authorization for a booster shot for Novavax’s coronavirus vaccine.” The FDA “said that people ages 18 and older can receive the booster six months after completing their first series of a United States-approved coronavirus vaccine.” Use of the booster allowed, the last step before the vaccinations can be administered”.

The AP (10/19, Dunn) reports that the agency also “said that the new booster option is for those ages 18 and older who, for medical or accessibility reasons, do not have updated Omicron targeting Pfizer or Moderna boosters—or who otherwise wouldn’t receive a COVID-19 booster shot at all.”

The Washington Post (10/18, O’Connor) reports on a study published in the New England Journal of Medicine showing “that people of all ages can achieve significant health benefits from eating highly processed foods with salt, sugar and other additives and replacing them with more nutritious foods like fruits, vegetables, nuts, beans, lentils, seafood, and whole grains.” In the study, the researchers “followed about 74,000 people between the ages of 30 and 75 for over two decades” and “found found that people with consistently high nutritional values ​​were up to 14% less likely to die from any cause during the comparison period than people who consistently had a poor diet.”

MedPage Today (10/17, Minerd) reports, “More than one million Americans with diabetes may be skipping insulin doses or postponing purchases of the drug because of its cost,” the investigators concluded. The “data from 982 insulin users who participated in the CDC’s 2021 National Health Interview Survey” show that “16.5% reported some form of rationing of the drug.” Should this finding “be representative of all Americans with diabetes, it could mean that more than a million patients are rationing insulin with potentially harmful consequences, the researchers wrote in a brief report” published online in a research letter in the Annals of Internal Medicine became.

Medscape (10/17, Tucker, Subscription Publication) reports, “Unsurprisingly, those without insurance had the highest rationing rate at nearly one-third,” but those “with private insurance also had higher rates than the overall diabetes population, at nearly one in five.” .” Patients “with public insurance — Medicare and Medicaid — had lower rates.” The study authors “also note that the $35 insulin co-payment cap included in the Inflation Reduction Act of 2022 could improve insulin access for Medicare beneficiaries, but a similar cap for privately insured members has been removed from the bill” and “co-pay Insulin cap “Salary caps don’t help people who don’t have insurance.”

MedPage Today (10/15, George) reported: “Signs of brain damage appeared as early as nine years before diagnosis of Alzheimer’s or other dementia-related diseases,” concluded researchers in a study that “assessed baseline cognitive and functional scores in 2,778 participants, who later developed Alzheimer’s, 2,370 who developed Parkinson’s, 211 who developed frontotemporal dementia, 133 who developed progressive supranuclear palsy, 40 who developed dementia with Lewy bodies, and 73 who developed a developed multiple system atrophy”. Next, the study team “compared these individuals to baseline data from 493,735 biobank controls who were not subsequently diagnosed with a neurodegenerative diagnosis.” The results were published online in the journal Alzheimer’s & Dementia.

AMA Morning Rounds coverage is developed in partnership with Bulletin Healthcare LLC. Subscribe to Daily Morning Rounds.


Leave a Reply

Your email address will not be published. Required fields are marked *